Oncolytics sees final PanCAN grant payment this quarter; GOBLET Cohort 4 data due Q4 2026

ONCOLYTICS BIOTECH INC

Oncolytics (Nasdaq: ONCY) expects the final Pancreatic Cancer Action Network grant payment later this quarter after completing Cohort 5 wind-down activities.
Final Cohort 4 results, testing pelareorep with atezolizumab in second-line or later squamous cell anal carcinoma, are expected in Q4 2026.
Initial Cohort 5 results in first-line metastatic pancreatic ductal adenocarcinoma are expected in H1 2027, but could slip as patients stay on treatment.
CMO Thomas Heineman said Cohort 4 median overall survival exceeds the company's expectations, with the full data set still being processed.
Oncolytics said every GOBLET cohort that enrolled the required number of patients met its pre-specified efficacy success criteria.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.